Study Links Thymulin Loss to Weaker Cancer Immunotherapy in Older Adults, Boosting Mouse Survival
Updated
Updated · health.yahoo.com · Jul 28
Study Links Thymulin Loss to Weaker Cancer Immunotherapy in Older Adults, Boosting Mouse Survival
2 articles · Updated · health.yahoo.com · Jul 28
Summary
Older mice given thymulin showed lower tumor inflammation, stronger T-cell activity and better immunotherapy responses, with slower tumor growth and improved survival.
The study traced the age-related treatment gap to the thymus: after puberty the gland shrinks, thymulin levels fade, and myeloid cells begin producing excess inflammatory proteins that can help tumors grow.
Human blood samples and breast tumor tissue from older patients showed the same inflammatory pattern, suggesting the mouse findings may reflect a broader aging-related immune shift.
This remains preclinical work in mice and lab-tested human cells; thymulin is not an available therapy, and translating the pathway into treatments will require years of clinical research.